logo
The 2nd Biopharm
Innovationand Development Summit
1-2 Dec. 2015
A multi-dimensional interactive
platform waiting for you to attend

HOTEL NIKKO NEWCENTURY BEIJING
  • CPhI China 2014

    Join More Than 250 Attendees at Asia's Most Important Biopharmaceutical Summit

  • CPhI China 2014

    Join More Than 250 Attendees at Asia's Most Important Biopharmaceutical Summit

  • CPhI China 2014

    Join More Than 250 Attendees at Asia's Most Important Biopharmaceutical Summit

  • CPhI China 2014

    Join More Than 250 Attendees at Asia's Most Important Biopharmaceutical Summit

Organizer

Co-Organizers
北京亦庄生物医药园

About

Many pharmaceutical manufacturers consider China as one of the most important strategic markets for future growth. China is projected to become one of the world's major biopharmaceutical players, along with the US, Europe, and Japan. Now that China has opened its window to the world, its biopharmaceutical industry will see more opportunities.

That’s where “The 2nd Biopharm Innovation and Development Summit (BioLink Summit)” comes in. Together with leading experts who breathe China’s opportunities, BioLink Summit will explore China’s market; present the progress of its biopharmaceutical industry and discusses their potential impact.

Backed by sponsors, partners and industry stakeholders who stay true to the BioLink Summit brand, it is a testimony of how we can only be bigger and better as we mature along with China’s biopharmaceutical industry.

Welcome to “The 2nd Biopharm Innovation and Development Summit”

Speakers

Ming-de Xia
Senior Director of New Ventures, Johnson & Johnson
Joseph Cho
Managing Director, RDPAC
Bing-bing Feng
Vice President and General Manager, USP-China
Hong-qi Wang
Vice President, BGI.
Xiao-chun Cao
Deputy General Manager,
Hangzhou Tigermed Consulting
Julius Li
CEO
AutekBio China
Xiao-bo Qiu
Professor
College of Life Sciences, Beijing Normal University
Jin-qun Yin
Vice President,
KangHong Pharmaceutical Group
XIN LIU
heads the China office of GPC
Jiangnan (John) Cai
Director for CEIBS Center for Health Management and Policy
Xin He Haibin Wang
Senior Vice President
Kang Li
Head of Biologics
BeiGene, Ltd.
Petr Janda
Accord Research
Feng Zhou
Product & Solution Specialist
Zhongping Guo
Director of biological standards division
Chinese Pharmacopoeia Commission(ChPC)
Yinxing Wang
president & CSO
Betta pharmaceuticals Co.Ltd
WU SONG
Professor and Head of the Department of R&D.
Institute of Materia Medica, CAMS & PUMC
Feng Tian
Chief Scientific Officer
Ambrx Inc.
Cherrie Che
Head of BHC Strategy and Sales Excellence,China
Bayer Healthcare Co., Ltd.
Chiang Syin
Associate Country Director, FDA China Office
GUO FENG
Head of Merck R&D China
Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd
Meng Dongping
Vice President of CCCMHPIE
Tao Feng
General Manager of Investment Department
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Zhou Aiping
Professor
Cancer Hospital Chinese Academy of Medical Sciences

Ming-de Xia
Senior Director of New Ventures, Johnson & Johnson

Dr. Mingde Xia is currently a Senior Director of Johnson & Johnson Innovation Center in Asia-Pacific, and a vice Chair of Asian Society for Innovation & Achievement (A.S.I.A.) in USA and Canada. He focuses on business development in mainland China, Hong Kong, Taiwan, and Korea etc. with universities, institutes, investors and innovative companies for J & J worldwide pharmaceuticals, medical device / diagnostic products and OTC / consumer business, through investment, incubation, co-development, license and other collaboration vehicles. He has been working with Johnson & Johnson for 16 years after career track at China Pharmaceutical University and Yale University, and has successfully led / executed over 50 projects external collaboration for Johnson & Johnson three sectors. He is a guest / adjunct professor at the Chinese Academy of Sciences, a major inventor / author of over 60 patents / publications, a reviewer for a number of top quality international scientific journals, and an invited speaker for many international pharmaceutical conferences / forums. He received awards from American Chemical Society, Johnson & Johnson and different universities. He has actively involved in Sino-American Pharmaceutical Professionals Association (SAPA President 2008-2009, Board of Directors 2008-2015) and organized many international conferences in USA and Asia.

Joseph Cho
Managing Director, RDPAC

Mr. Joseph Cho was appointed as Managing Director of China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC)on April 1, 2011. Joseph is a very knowledgeable and experienced pharmaceutical industry leader, with 38 years’ experience in pharmaceutical industry in China, Japan, Hong Kong and Taiwan.

Since 1999, Joseph has been very active in supporting RDPAC as the Executive Committee member. From 2008 to 2011, he has been acting as Vice Chairman for RDPAC and plays a great role in RDPAC. Having spent more than a decade running a pharmaceutical operating company in China, Joseph fully understands the opportunities and threats facing the industry.

Joseph has been engaged in policy research and advocacy activities in the area of pharma innovation, national health insurance systems, drug regulatory, market access and business ethics for the R&D Pharma industry associations in Taiwan, Hong Kong, Mainland China and Japan as council members or industry experts.

Before joining RDPAC as Managing Director, Joseph was Country Manager and Chairman of the Board of Astellas Pharma China. Joseph started off his career as a medical representative in Fujisawa Taiwan in 1977, and then took on increasingly many important jobs in Fujisawa (now known as Astellas after merging with Yamanouchi in 2005) in the past 35 years.

Joseph graduated from National Taiwan University, and he is member of Rotary Club, which dedicates to combat hunger, improve health and sanitation, provide education and job training, and promote peace.

Bing-bing Feng
Vice President and General Manager, USP-China

Bingbing Feng, Ph.D., is Vice President and General Manager of USP-China.  He oversees administrative and laboratory operations at USP’s state-of-the art, award-winning facility in the Shanghai Pilot Free Trade Zone.

Dr. Feng brings more than fifteen years of pharmaceutical and contract research industry experience, both in the United States and China, to his leadership role at USP.  Prior to joining USP, he served as Vice President of Business Development at Alliance Pharma.  His previous industry positions include leadership roles in management and operation, business development, global manufacturing and supply, and research and development at companies that include Shanghai Medicilon, Inc., Frontage Laboratories, Inc., Kelly Services at McNeil Consumer Healthcare (Johnson & Johnson), and GlaxoSmithKline.  

Dr. Feng earned his Ph.D. in Analytical Chemistry from Purdue University and his Bachelor of Science degree from James Madison University.  He completed his postdoctoral research fellowship at the United States Department of Energy’s Pacific Northwest National Laboratory.

Hongqi(Hank) Wang, Ph.D.
Vice President, BGI; Chief Executive Officer, BGI-LiuHe; General Manger, BGI-North China

With nearly 20 years of senior executive experience in domestic and foreign companies, Dr. Wang once served as the general manager of Greater China in Bruker Daltonics Inc, a top global manufacturer of bioanalytical instruments.

Before joining Bruker, Dr. Wang worked for Millenium Pharmaceuticals Inc. (USA) as a senior scientist in the field of natural product and combinatorial library screening by high-throughput LC/MS/BioAssay technology. Besides, Dr. Wang held multiple positions in Perseptive Biosystems (acquired by ABI) starting as a senior scientist, then lab manager, and product manager.

Dr. Wang graduated from Shandong University majoring in biology. In1986,he was chosen as one of the top fifteen students in China who were awarded the scholarship of CUSBMBEA Program--a China-US Biochemistry & Molecular Biology Examination and Application program, through examinations and interviews by the U.S.A top university examination board. Afterwards, he got his PHD of Analytical Biochemistry in Purdue University. Besides, he also received an EMBA from Perking University.

Dr. Wang is currently member of many scientific and commercial associations and has more than 10 scientific publications.

Xiao-chun Cao
Deputy General Manager, Hangzhou Tigermed Consulting

The founder, Executive Vice President, Board Secretary of Hangzhou Tigermed Consulting Co., Ltd.

 Experiences with Bio-medicine R&D, Clinical Research for over 20 years and more than 10 years of CRO management experiences.

Julius Li
Co-founder of AutekBio, Inc and CrownBio, Inc.

He also led AutekBio as its CEO to obtain multi-million US dallors to build the first US / EU cGMP facility for therapeutic biologic manufacturing. AutekBio is the first biologic Contract Manufacturing Organization professionally operating in China. CrownBio raised about tens of millions USD to become a leading biologic platform organization for new drug developments with significant amount of revenues. Julius has taken technical and management positions in US and Chinese pharmaceutical companies, from startups to multinationals, such as Guangzhou Baiyunshan Pharmaceutical Group, Hoffmann La-Roche and Asterand. Mr. Li earned graduate degrees from Zhongshan University, Chinese Centers for Disease Control and Prevention and the Ross Business School at the University of Michigan. He is also the current Deputy Director General of the National Engineering Center for Viral Biotechnology.

Xiao-Bo Qiu, Ph.D.,
Professor, College of Life Sciences, Beijing Normal University

Dr. Qiu received his Ph. D. at Molecular Pharmacology & Toxicology from University of Southern California in 1996, worked as a Research Fellow at Harvard Medical School in 1997-2005 and as a Staff Scientist at Burnham Medical Research Institute in 2005-2006. He served as a professor at Chinese Academy of Medical Sciences/Peking Union Medical College in 2005-2008, and then started to work at Beijing Normal University from 2008. His researches mainly focus on protein modifications and degradation and their roles in regulating cell survival and apoptosis (Qian et al., Cell, 2013; Wang et al. Nature Immunology, 2015). He received a distinguished youth award from the Natural Science Foundation of China, and was selected as a national talent of the “hundred, thousand, and ten-thousand talents” project.

Yinjinqun
VP of Kanghong Pharmaceutical Group

Head of marketing, medical, sales, training, enterprise brand promotion and public relations of Kanghong Group Graduate from Beijing International MBA at Peking University, BiMBA

15 years working experience in Multinational Pharmaceutical Companies, starting in Xian~Jassen Pharmaceuticals as a sales representative through regional director; In early 2008, he joined in Bayer Pharmaceuticals as Western China director of generic medicine;

In 2009, he served as the national director of antithrombotic business unit, and successfully launched Bayer’s global strategic product Xarelto (Rivaroxaban )in China and uplifted the classic Bayaspirin to best seller in market share;

In 2011, he led and implemented Bayer’s “Chinese Growth strategy”, working as director of emerging market development department.

He established a new model of“integrated promotion of all products” to guide multinationals to enter China’s 4th and 5th-tier cities. Now most of the regional managers responsible for similar business at foreign-invested Pharmaceutical companies in China used to be his team members.

XIN LIU
heads the China office of GPC

Xin as Managing Director, heads the China office of GPC, a London-based private equity firm focused on investments in healthcare and IT. She led Ready Medicine’s RMB6n backdoor listing on the A-share market by joining force with a group of Chinese domestic private equity funds. Xin also led an equity investment by Fosun in GPC’s Chinese/US specialty generic pharmaceutical company, which Xin helped to refocus the strategy and manage the turn- around within 2 years.

Previously, Xin was the head of business development Asia Pacific & Emerging Markets for GlaxoSmithKline London, where she was responsible for business development strategies and opportunities within China, India, Russia and other Asian countries. She originated and executed a number of strategic acquisitions, including the takeover of a Chinese Urology pharmaceutical group, and a Chinese dermatology company as well as numerous product/assets acquisitions in India, South East Asia and Russia.

Prior to GSK, Xin was working at Business Development for Hoffmann-la Roche headquarters in Switzerland, where her main focus was to acquire innovative drugs, technology platforms and biotech companies in US, Europe and Japan. She led the global divestment of three well established Roche brands to Meda AB (Sweden) for CHF 250m. She masterminded the spin-off of Roche Pain/Respiratory Research & Development business and set up a start-up biotech company ‘Afferent Pharmaceuticals’ with 4 US VC firms to further develop this Roche’s R&D pipeline.

Her 18 years of experience includes leadership positions in corporate M&A, Business Development, Research/Development and Marketing/sales with GSK, Hoffmann-la Roche and Eli Lilly.

She holds a Master degree in Molecular Biology with additional qualification in Business Administration from the University of Cologne, Germany, where she won scholarship from Friedrich-Naumann-Foundation for her study.

Jiangnan (John) Cai
Director for CEIBS Center for Health Management and Policy

Prof. Cai is the Director of Center for Healthcare Management and Policy and Adjunct Professor of Economics at China Europe International Business School (CEIBS). He has been involved in teaching, research and consulting work at universities, consulting firms and government in the area of healthcare over twenty years in both U.S. and China. He has published extensively in the areas of health economics and health policy. He participated in the design, implement and evaluation of the first comprehensive health care reform plan (Massachusetts) in the U.S. and was also actively involved in design of the new health care reform plan in China.

Prof. Cai was the cofounder of the Institute of Economic Development and Business School at the East China University of Science and Technology (Shanghai) and the first Chair of Department of Public Economics at Fudan University. He received 1990 Sun Yie-fang National Economic Science Prizes-Best Paper Award, 2002 Most Outstanding Abstract Award by AcademyHealth in the US, and 2009 Excellent Paper Award from Shanghai Social Science Annual Conference. He received Ph.D. in Public Policy from the Heller School for Social Policy and Management at Brandeis University in 1997 (US), his MA in Economics at Fudan University in 1984 and his BA in Economics at East China Normal University in 1982.

Haibin Wang
Senior Vice President

PDr. Haibin Wang was named as the professor-level senior engineer. She currently serves as director on the board of Zhejiang Hisun Pharmaceutical Co., Ltd. She is also serving as the senior vice president of the company leading the entire biopharmaceutical division. She has over 20 years of experience in the biopharmsuetical industry, ranging from R&D of microbial fermentation and biotheraptuics to the drug registration and commercial scale pharmaceutical production,and leading more than ten products into market. She has more than 30 publications and patents in local and international journals.

Kang Li
Head of Biologics BeiGene, Ltd

•Former executive director, Pfizer-CrownBio Asian Cancer Research Center, Crown Bioscience
•Former senior principle scientist, group and project leader, Pfizer-La Jolla Laboratory, Oncology Research Unit
•Former senior scientist, Tanox, Inc. (acquired by Genentech)
•Post-doc and assistant professor, UTSW Medical Center at Dallas
•Ph.D. in biochemistry and molecular biology, Emory University, US
•MBA, University of Dallas, US
•M.S. in cell biology and genetics, Wuhan University, China
•B.S. of biology, Henan Normal University, China

Petr Janda
CEO, Accord Research

Petr Janda is a medical doctor, graduated in 1984 from Charles University, Prague, Czech Republic with a specialisation in Internal Medicine and Nephrology. In 1998 he completed two years Postgraduate Study in Pharmaceutical Medicine, University of Wales, Cardiff (UK) focused on organisation and running of the drug development. He has over 25 years of experience in organising and executing various clinical studies, in particular within Ciba Geigy, Ferring (Head of Clinical and regulatory department) and Prague Clinical Services (CEO). He has been responsible for worldwide clinical studies from phase I – IV, as well as registration and pharmaco-vigilance activities. An important part of Mr.Janda work was the organisation and execution of various clinical studies for non-European (Japan) partners including bridging studies with European population. Because of these activities Mr.Janda is deeply oriented in the problematic of bridging studies between Asian and Caucasian populations and he understands the mechanism of the penetration of Asian sponsors to European market. Mr.Janda is currently CEO of Accord Research. Accord Research is an independent full service Clinical Research Organisation (CRO), member of PPF Group, operating in the most European countries and partially in the USA. Accord Research assures for the sponsors full service cooperation in the clinical research field including support to non-European companies willing to penetrate to the European market. Moreover Mr. Janda is the President of the Czech CROs Association ACRO-CZ, member of the European CROs Association EUCROF. ACRO-CZ is taking care of rights and obligations of all professionals working on the field of the drug development. ACRO-CZ closely cooperates with regulatory bodies and is one of their partners during approval processes concerning the clinical development legislation. Mr. Janda is active in various teaching programs, seminars and congresses concerning the drug development in the Czech Republic and abroad.

Feng Zhou
Product & Solution Specialist

Dr. Zhou Feng joined Thomson Reuters as Product & Solution Specialist in May, 2015. Prior to this position, he was Director of Business Development of Innovent Biologics. Before that he was an Senior Manager of Business Development at Simcere Pharmaceutical Group from 2010 to 2014. Feng earned his PhD in Biochemical Pharmacy from China Pharmaceutical University.

Zhongping Guo
Director of biological standards division
Chinese Pharmacopoeia Commission(ChPC)

Ms Guo joined ChPC in 2004,and has got involved in the management of Chinese national biological standards which is known as Chinese Pharmacopoeia (ChP) Vol. Ⅲ.since then. Before joining ChPC, She had about 20 years working experience in biological industry.

Yinxing Wang
president & CSO
Betta pharmaceuticals Co.Ltd

Yinxiang Wang: President & Chief Scientist, PhD, successively engaged in postdoctoral research in molecular biophysics and biochemistry at Yale University, returned to China in 2003 and founded the Beijing Innovative Drug R&D Center of Betta Pharmaceuticals. Served concurrently as a distinguished professor for the New Drug Safety Assessment Center of Chinese Academy of Medical Sciences. Served as a distinguished professor for the New Drug Safety Assessment Center of Peking Union Medical College, Chinese Academy of Medical Sciences in 2006. Selected to be a member of the New Century “131” Outstanding Young and Middle-Aged Talents Training Plan of Hangzhou in 2007; winner of the special allowance of Hangzhou in 2010; selected to be a member of “Hangzhou ‘521 Recruitment Program’ of Global Talents” in 2011; rated as high-quality overseas professionals of new districts of Beijing in 2011; selected to be a member of the national “Recruitment Program of Global Experts” in 2012.

Wu Song
Professor and Head of the Department of R&D
Institute of Materia Medica, CAMS & PUMC

Professor Wu was born in 1964. His research is mainly engaged in the research and development of innovative drugs and generic drugs. Professor Wu is the Director of the Department of New Drug Research and Development, Institute of Materia Medica, CAMS & PUMC, and he is also served as a member of the drug review committee of the State Food and Drug Administration, member of the veterinary drug review committee of the Ministry of Agriculture, and member of the State Pharmacopoeia Committee at present. He has published more than 100 papers.
In the development of generic drugs, he have successful developed more than 30 products , which have achieved great economic and social benefits.

Feng Tian
Chief Scientific Officer
Ambrx Inc.

Feng Tian, Ph. D. has held increasing roles of responsibility at Ambrx since joining the company in 2004. Currently, as Chief Scientific Officer, Dr. Tian oversees company’s research and development. During the tenure at Ambrx, Dr. Tian is instrumental in the establishment and improvement of Ambrx technology and product platforms.
He played a key role in the establishment of EuCODE technology platform (site-specific non-natural amino acid incorporation in eukaryotic cells); he led teams to establish Ambrx site-specific antibody drug conjugate (ADC) technology platform, ADC pipeline and “Switch” vaccine platform. More recently, on the business side, Dr. Tian initiated and established Ambrx China Strategy. He played a central role in building China collaborations, and most recently, in Ambrx M&A. Prior to joining Ambrx, Dr. Tian conducted his postdoctoral study at The Scripps Research Institute where his work involved catalytic antibodies, non-natural amino acid incorporation and biosensors. Dr. Tian received his Ph. D. in Chemistry from the University of Florida with a dissertation in the field of physical organic chemistry and received his B. S. in Chemistry from Peking University.

Cherrie Che
Head of BHC Strategy and Sales Excellence,China
Bayer Healthcare Co., Ltd.

• Over 15 years of pharmaceutical experience in both China and Australia, and 6 plus years of professional consulting experience at Boston Consulting Group and Ernst & Young
• ‘Rising Star Award’ (2010) from the Healthcare Business Women’s Association (HBA) in New York, as the 1st winner from China for this award
• More than 10 publications in international peer reviewed journals • PhD in Pharmacology (Australia)

Currently Dr. Cherrie Che holds the office of BHC Strategy and Sales Excellence China Head, leading 100 people team to enable Bayer Healthcare’s business operation in China.

Chiang Syin,
Associate Country Director, FDA China Office

Dr. Chiang Syin is currently the FDA Associate Country Director in Beijing. His responsibility is managing the Office’s drug and device inspection program. Prior to joining the China Office, he served as Branch Chief in the Division of Manufacturing and Product Quality of the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. In this position, he provided leadership and program guidance to the staff engaged in Chemistry, Manufacturing and Control (CMC) reviews and Good Manufacturing Practice (GMP) inspections for premarketing license applications and post marketing changes of the biological products.

He first joined CBER in 1988 after his postdoctoral training in NIAID, NIH. Dr. Syin is actively involved drafting Vaccines CMC and Phase I GMP guidance documents as well as the 2011 Process Validation guidance revision. Dr. Syin received his Ph.D. in chemistry from the Catholic University of America and a B.S in biology from the Tunghai University in Taiwan.

GUO FENG
Head of Merck R&D China
Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd

Dr. Feng Guo, PhD, is the Head of R&D at Merck Serono China. He joined the company in May, 2013.

In this capacity, Dr. Guo is responsible for leading drug development for China/Asia Regional clinical trials; contributing to global drug development; ensuring earlier and successful registration of products in China; and focusing research activities on translational research.

He is also responsible for building the strategic direction of R&D for Merck Serono in China, in partnership with commercial leadership to enhance Merck Serono’s position and reputation as a scientific leader in biopharma.Dr. Guo obtained his PhD in Clinical Parma Oncology from University of Toronto.

Meng Dongping
Vice President of CCCMHPIE

Madam Meng,Vice President of CCCMHPIE. Master degree of International Economics from Namur University, Belgium and Bachelor degree of International Trade from Nankai University. She has been committed to promoting the upgrading and internationalization of the Chinese healthcare industry. On one side, she is very active in formulating government trade and regulatory policies such as trade facilitation and revision of drug administration law, coordinate and reflect interests of the industry, guarantee the right of companies, help companies gain a bigger policy support, facilitate problems solving. On the other side, she is good at coordinating and communicating with oversea governments, participates in WTO and WCO harmonization system, solved a series of problems such as EU No. 62 directive, and create a good environment for sustainable development of international trade in healthcare area. She has taken many Chinese healthcare delegations to developed markets such as US, UK, France, Italy, Japan and Korea, and emerging markets including Russia, Estonia, Southeast Asia, Kenya, Tanzania, Ukraine and Bulgaria to launch industry exchange dialogues and match-making programs with local companies, all of which are warmly received by the local healthcare industry as the programs are always professional, practical and effective.

She worked in the Department of Policy Research, Department of Trade Policy and Development, the Department of WTO of Chinese Ministry of Commerce. She is very active in the research and formulation of national foreign trade and economic policies, and management of foreign trade. She has published dozens of articles on domestic and abroad magazines. Besides, She drew up articles for several national leaders and won the AnZijie International Trade Dissertation Award.

Tao Feng
General Manager of Investment Department
Shanghai Fosun Pharmaceutical Group Co., Ltd.

Since 2013, Mr. Tao Feng is acting as the General Manager of Investment Department of Shanghai Fosun Pharmaceutical Group Co., Ltd., the venture and PE arm of this leading Chinese healthcare enterprise. Before that, Mr. Tao owns over 10 years experience as operation, management and investment executive in China's healthcare industry primarily within Fosun Pharma, Fosun Group and China Resource Group. Mr. Tao and his team made a series of successful deals in pharmaceutical, medtech, medical service, and mobile health industries. Representative deals include: Dean Diagnostic (300244.SZ), Dirui Medical (300396.SZ), Wego Group (1066.HK), Shanhe Pharmaceutical Excipients (300452.SZ), Chongqing Pharma Group, Chindex, Guahao.com, etc..

Besides, Mr. Tao is the Board member of Hansen Pharma (002412.SZ) and Shanhe Pharmaceutical Excipients (300452.SZ). Mr. Tao holds his Bachelor Degree from Tongji University and his MBA from Shanghai University of Economy and Finance.

Zhou Aiping
Professor
Cancer Hospital Chinese Academy of Medical Sciences

Zhou Aiping, professor of medical oncology of cancer hospital Chinese academy of medical sciences. Professor and vice director of department of medical oncology of Chinese Academy of Medical sciences & Peking Union Medical College (CAMS & PUMC). She got her Ph.D from CAMS & PUMC Beijing in 2001 and M.D from Beijing Medical University, P. R. China in 1993.

Clinical Experience:
2013.9- Professor, Dept. of Medical Oncology, Cancer Hospital, CAMS & PUMC.
2004.9- 2013.8 Associate professor, Dept. of Medical Oncology, Cancer Hospital, CAMS & PUMC.
2001.8- 2004.8 Attending, Dept. of Medical Oncology, Cancer Hospital, CAMS &PUMC.
1993.8-2001.7 Resident, Dept. of Medical Oncology, Cancer Hospital, CAMS&PUMC.

The 2nd BioLink

- The 2nd Biopharm Innovationand Development Summit

Dec.1-2, 2015, Beijing

Highlights:

  ●A multi-dimensional interactive platform-Keynote speeches+ panel discussions+ project showcase+ exhibition
  ●Authoritative trend analysis of Chinese biopharmaceutical industry-analysis on landscape of therapeutic biologics on a global scale
  ●A comprehensive showcase of internationally-leading biopharma technologies- immunotherapy+ precision medicine+ R&D and production of therapeutic biologics
  ●A detailed guide to decision-making of venture capital-great financing opportunities for biotech start-ups
  ●An array of projects promotion towards tech transfer, financing and M&A
  ●The greatest occasion to meet 200+ industry players

Agenda

DAY  ONE DAY TWO
9:00-12:10 Meeting:Module 1 Exhibition 9:00-10:30 Meeting:Module 5 Exhibition
13:30-15:30 Meeting:Module 2
15:30-18:30 Parallel Meetings:Module 3-4 10:50-12:00 Project Showcase:Module 6

DAY 1:DEC.1, 2015
Module 1: Industry Development and Updates on Regulatory Policies and Standards(3rd Floor Century Hall)
9:00-9:10Opening Address from Chairman
Xia Mingde, Senior Director of New Ventures, Johnson & Johnson Innovation
9:10-9:20Opening Address
Xu Ming, Vice President, CCCMHPIE
9:20-9:50Building an Innovation-Driven Ecosystem for Bio-Pharma Industry in China
Joseph Cho, Managing Director, RDPAC
9:50-10:20Current Development of Health Policy and Health Sector Innovation in China
John Cai, Director, Center for Healthcare Management and Policy of CEIBS
10:20-10:50Regulating Therapeutic Biologics-A View Of Chinese New Pharmacopeia
Guo Zhongping , Director of biological standards division, Chinese Pharmacopoeia Commission
10:50-11:10Tea Break and Networking
Visit the exhibition area and to network with 200+ industrial peers
11:10-11:40 Overview of the US Biologicals Market in the US and Ensuring Commercial Success
Trey Putnam , VP and GM of Regulatory Science, Cardinal Health Specialty Solutions
11:40-12:10looking into 2016: Impact of the Financial Markets on Globalization
David Flores, President and CEO, BioCentury
12:10-12:20Introduction On SGX Listing Platform
Jeanette Li, Deputy Representative, Singapore Exchange Beijing Representative Office
12:20-13:30 Lunch
Module 2: Global Biopharmaceutical Market Dynamics
13:30-14:00Biosimilars clinical trials in EU
Petr Janda, CEO, Accord Research
14:00-14:30Key Consideration on Biologicals Review and Case Studies
Chiang Syin, Associate Country Director, FDA’s China Office
14:30-15:00Overview of Biologics Standard Development at United States Pharmacopeia
Feng Bingbing, Vice President and General Manager, USP-China
15:00-15:30Research and Markets---Global Biologics Perspectives
Zhou Feng, Product & Solution Specialist, Thomson Reuters
15:30-15:50Tea Break and Networking
Visit the exhibition area and to network with 200+ industrial peers
15:50-18:30Parallel SessionModule 3:
Immune therapy and Precision Medicine
Module 4:(3rd Floor Century Hall)
R&D and Production of Therapeutic Biologics
Moderator:
Xu Ming, Vice President, CCCMHPIE
Keynote 1:
Immunotherapy, Changing Landscape of Cancer Treatment
- Li Kang, Head of Biologics, BeiGene
Keynote 2: Genetic Technology and Precision Medicine
-Wang Hongqi,Vice President,BGI
Panel Discussion:
• Development Prospects of Precision Medicine.
• Impact of immunotherapy on tumor research development.

- Li Kang, Head of Biologics, BeiGene
- Wang Hongqi,Vice President,BGI
- Wang Yinxiang, President & CSO, Betta Pharmaceuticals
- Wu Yanzhuo, Vice President, Beijing SL Pharmaceutical
- Zhou Aiping, Professor, Cancer Hospital Chinese Academy of Medical Sciences
Moderator:
Xia Mingde, Senior Director of New Ventures, Johnson & Johnson Innovation
Keynote 1:
Drug Targets in the Ubiquitin-Proteasome
Pathway
-Qiu Xiaobo, Professor, College of Life Sciences, Beijing Normal University
Keynote 2:
Site-Specific ADC by Design-using an Expanded Genetic Code
-Tian Feng, CSO, Ambrx
Panel Discussion:
• Biopharmaceutical R&D Hot Area in the Recent Future.
• Paths for Enterprises to improve R&D productivity.

- Qiu Xiaobo, Professor, College of Life Sciences, Beijing Normal University
- Tian Feng, CSO, Ambrx
- Wu Song, Head of the Department of R&D, Institute of Materia Medica, CAMS & PUMC
- Wang Haibin, Senior Vice President,Hisun Pharmaceutical
- Guo Feng, Head of R&D China, Merck Serono
- David Flores, President and CEO, BioCentury
DAY 2:DEC.2, 2015
9:00-10:00Module 5: Biopharmaceuticals and Financing(3rd Floor Century Hall)
Moderator:
Meng Dongping, Vice President, CCCMHPIE
Panel Discussion:
• How biopharmaceutical enterprises can become more attractive to investors?
• Experiences in financing model of foreign biopharmaceutical enterprises.

Cherrie Che, Strategy and Sales Excellence, Bayer China
Cao Xiaochun, Executive Vice President, Hangzhou Tigermed Consulting
Sylvia He, Partner, CDH Investments
Julius Li, CEO, AutekBio China
Shao Qun, Deputy Director, Open Innovation University of Bradford
Tao Feng, General Manager of Investment Department, Shanghai Fosun Pharmaceutical Group
Yin Jinqun, Vice President, KangHong Pharmaceutical Group
10:00-10:20Tea Break and Networking
Visit the exhibition area and to network with 200+ industrial peers
10:20-12:30Module 6: Roadshow
Life Science Road Show for Financing and M&A
Co-organizer: eChinaChem, Inc.
• Market development of biomedicines and comsumer healthcare products from medicinal Cordyceps fungi
• Active hydraumatic ventricles support drug delivery system
• Natural Active Substances Extraction of Bark
• X803 - a Novel Targeted Anticancer Small Molecule Therapeutics
• New Cancer Diagnostic and Therapeutic
★Close-door Meeting
Life Science Technology Transfer Projects Road Show(3rd Floor Century Hall)
• CBBC Projects (10:20-10:40)
• A Broad Spectrum Tumor Kit(10:40-10:50)
• α-Linolenic acid (10:50-11:00)
• A Novel Therapeutic for the Treatment of Urge Incontinence
• A Novel Therapeutic for Malaria(11:00-11:20)
• Huaxin Pharmaceutical Factory Transfer(11:20-11:30)
• Suvorexant (11:30-11:40)

Media Partners

Integrated Marketing Solutions

CPhI.cn——China's leading B2B Marketplace for Pharmaceutical IndustryMedia——Cooperation with Worldwide Authoritative Media
Email Blasting——More Than 6,949,673 Emails Sent to Professional Data Base Wechat——Mobile Marketing Promotions
Weibo——Weibo.com/cphi Interactive Activities though Instant Info SharingDirect Mailing——More Than 552,206 Mails Directly Sent to Industry Players
APP ——Cphi-app.com/chinaConferences——Best Practices Sharing & Case Studies Brainstorming
TOP